The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants.

Front Pharmacol · 2022 · PMC9574342 · PMID 36263131

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results showed that although GMB-475 showed a trend of reducing the tumor burden ( Figure 3C,D ) and prolonging the survival of the CML mouse model ( Figure 3B ), its effect was limited and not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.